Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹140 Cr
Revenue (TTM)
₹88 Cr
Net Profit (TTM)
₹14 Cr
ROE
12.8 %
ROCE
17 %
P/E Ratio
10
P/B Ratio
0.7
Industry P/E
26.59
EV/EBITDA
3.2
Div. Yield
0.4 %
Debt to Equity
0
Book Value
₹604.2
EPS
₹40
Face value
10
Shares outstanding
3,572,600
CFO
₹37.54 Cr
EBITDA
₹143.30 Cr
Net Profit
₹127.48 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Coral Laboratories
| -10.4 | -11.4 | -11.0 | -44.2 | 19.7 | 3.3 | -1.4 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Coral Laboratories
| -46.2 | 81.9 | 35.0 | 3.6 | -0.1 | 116.0 | -62.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Coral Laboratories
|
393.0 | 140.4 | 87.6 | 14.0 | 11.0 | 6.9 | 10 | 0.7 |
| 2,791.2 | 34,920.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.4 | 7.6 | |
| 7,827.5 | 19,544.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.3 | 23.5 | |
| 1,565.8 | 11,917.5 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.4 | 3.6 | |
| 1,332.1 | 18,429.0 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.7 | 5.1 | |
| 1,961.1 | 31,410.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.8 | |
| 4,887.1 | 22,333.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.2 | 5.6 | |
| 4,778.6 | 7,918.9 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27 | 11.4 | |
| 388.9 | 7,603.2 | 1,432.0 | 149.0 | 19.1 | 7.9 | 50.7 | 3.1 | |
| 971.2 | 8,938.5 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.5 | 3.0 |
No Review & Analysis are available.
Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethopia, and internationally. The company offers antibiotics/antibacterial products, including antifungal, antiemetic, analgesics/antipyretic/antiinflammatory,... antispasmodic, anticold, antiallergic, antiasthmatic, antidiabetic, antiemetics, anthelmentic, thyroid, and antiprotozoal/antiamebic products; antimalarial drugs, antipsychotic drugs, gastro-intestinal drugs, kits, muscle relaxants, cough suppressant/expectorant products, cardiovascular medicines, oral antiseptic preparations, mouthwashes, calcium preparations, and appetizers; and nutritional, protein, and iron supplements, as well as other products. It also provides cephalosporin, beta lactam, and lyophilized injectable products; eye/ear/nose drops; nasal sprays and metered dose inhales; and large volume parenteral products. In addition, the company offers various nutraceutical products, such as dietary supplements, herbal/phytochemicals, multivitamins, and nutrients, as well as OTC products. It provides its products in various dosage forms, including tablets, capsules, low RH facilities, liquid orals, liquids and powders, dry syrups, drops, ointment and creams, gels and lotions, granules powders, injectables, nasal sprays, and suppositories. Coral Laboratories Limited was incorporated in 1994 and is headquartered in Mumbai, India. Read more
Incorporated
1997
Chairman
Sushma Kadkade
Managing Director
--
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Coral Laboratories Ltd is ₹392.95 (BSE) as of 02-Apr-2026 IST. Coral Laboratories Ltd has given a return of 19.74% in the last 3 years.
The P/E ratio of Coral Laboratories Ltd is 10.04 times as on 02-Apr-2026, a 62 discount to its peers’ median range of 26.59 times.
The P/B ratio of Coral Laboratories Ltd is 0.65 times as on 02-Apr-2026, a 86 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
10.37
|
1.25
|
|
2024
|
8.40
|
0.75
|
|
2023
|
12.69
|
0.53
|
|
2022
|
10.08
|
0.58
|
|
2021
|
8.49
|
0.84
|
The 52-week high and low of Coral Laboratories Ltd are Rs 784.55 and Rs 360.00 as of 04-Apr-2026.
Coral Laboratories Ltd has a market capitalisation of ₹ 140 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Coral Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹9.95
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.